Arbutus Biopharma (LTS:0SGC) Short Interest


LTS:0SGC Arbutus Biopharma Corp LTS:0SGC
53 GF Score
Price $3.32
GF Value $34.87
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0SGC vs EVMN, ANNX, TBPH: Short Interest Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arbutus Biopharma Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Short Interest falls into.


LTS:0SGC
53GF Score
Arbutus Biopharma Corp LTS:0SGC
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $3.32 is trading 90.5% below its estimated GF Value™ of $34.87.

Key valuation signals for LTS:0SGC:

  • Short Interest:
  • GF Value™: $34.87 vs. price of $3.32 (90.5% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges ABUS:USAI9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for LTS:0SGC

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price
$34.87
GF Value